NEW DELHI: The Drug Controller General of India has approved Sun Pharmaceutical Industries Ltd’s clinical trial with nafamostat mesilate in covid-19 patients.
Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of disseminated intravascular coagulation, a condition in which abnormal clumps of blood clots form inside blood vessels.
A group of scientists from the University of Tokyo in Japan and Leibniz Institute for Primate Research in Germany, however, have found that nafamostat, at very low concentrations, suppresses a protein that that the novel coronavirus uses to enter human lung cells, while another group from Institut Pasteur in South Korea found that the drug was able to inhibit virus
Read more on livemint.com